Aug 08, 2024 / 08:30PM GMT
Operator
Good afternoon and welcome, ladies and gentlemen, to Cytokinetics second-quarter 2024 conference call. (Operator Instructions)
I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Affairs. Please go ahead.
Diane Weiser - Cytokinetics Inc - Senior Vice President, Corporate Affairs
Good afternoon and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Fady Malik, EVP of R&D will provide updates related to SEQUOIA's HCM and the ongoing clinical trials program for aficamten. Chris Murray, SVP of Regulatory Affairs and Quality, will provide an update from our recent interactions with FDA and EMA and the progress of our planned regulatory filings.
Andrew Callos, EVP and Chief Commercial Officer, will address commercial readiness activities for aficamten. Stuart Kupfer, our SVP and Chief Medical Officer, will provide updates regarding on the omecamtiv mecarbil, CK-586 on our earliest-stage
Q2 2024 Cytokinetics Inc Earnings Call Transcript
Aug 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers